

**SciVision Biotech Inc.**  
**Board Meeting Resolutions**

Date	Important Resolutions
2025. 03. 06	<ol style="list-style-type: none"> <li>1.Approved the company's business plan in 2025.</li> <li>2.Approved the "Internal Control Declaration" in 2024.</li> <li>3.Approved the 2024 business report and financial statements.</li> <li>4.Approved the 2024 earnings and cash distribution for capital surplus.</li> <li>5.Approved the 2024 remuneration for employees and directors.</li> <li>6.Approved the 2025 compensation to directors and senior managerial officers.</li> <li>7.Appointment of the company's visa accountant and public fees.</li> <li>8..Proposal on the Base Date of Issuance of New Shares for the Second Domestic Unsecured Conversion of Corporate Bonds into Common Shares.</li> <li>9.Approved the agenda for holding of the 2025 annual general shareholders meeting.</li> <li>10.Approved the 2025 continuation of liability insurance policy for directors.</li> </ol>
2025. 05. 08	<ol style="list-style-type: none"> <li>1. Approved the Q1,2025 consolidated financial statements.</li> <li>2.Proposal on the Base Date of Issuance of New Shares for the Second Domestic Unsecured Conversion of Corporate Bonds into Common Shares.</li> <li>3. Approved the amendment of the company's "Articles of Incorporation".</li> <li>4. Approved the 2024 distributable compensation for directors.</li> <li>5. Approved the 2024 distributable compensation for employees.</li> <li>6. Apply for a Financial Institution Bank Account.</li> </ol>
2025. 08. 07	<ol style="list-style-type: none"> <li>1.Approved the Q2,2025 consolidated financial statements.</li> <li>2. Approved the renewal of banking facilities</li> <li>3. Apply for a Financial Institution Bank Account.</li> <li>4. Second Cash Capital Increase of CANDACE BIOMEDICAL INC.</li> </ol>
2025. 11. 13	<ol style="list-style-type: none"> <li>1.Approved the Q3,2025 consolidated financial statements.</li> <li>2. Approved the company's audit planning for 2026.</li> <li>3.Proposal on the Base Date of Issuance of New Shares for the Second Domestic Unsecured Conversion of Corporate Bonds into Common Shares</li> </ol>